

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7126867

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PHARMOSA THERAPEUTICS INC.	08/05/2020
RECEIVING PARTY DATA	
Name:	PHARMOSA BIOPHARM INC.
Street Address:	3F-3, NO.66, SANCHONG RD., NANGANG DIST.
City:	TAIPEI CITY
State/Country:	TAIWAN
Postal Code:	11560
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17511819
CORRESPONDENCE DATA	
Fax Number:	(703)997-7808
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2022366751
Email:	mail@pilloffpassino.com
Correspondent Name:	PILLOFF PASSINO & COSENZA LLP
Address Line 1:	2000 DUKE STREET
Address Line 2:	SUITE 300
Address Line 4:	ALEXANDRIA, VIRGINIA 22314
ATTORNEY DOCKET NUMBER:	203-011A
NAME OF SUBMITTER:	SEAN A. PASSINO
SIGNATURE:	/Sean Allen Passino, reg. no. 45943/
DATE SIGNED:	01/18/2022
Total Attachments: 2	
source=PA-2 PCT轉讓書 (PTI for PBI) _signed#page1.tif	
source=PA-2 PCT轉讓書 (PTI for PBI) _signed#page2.tif	

ASSIGNMENT

WHEREAS, Pharmosa Therapeutics, Inc., a Delaware corporation having offices at Corporation Trust Center 1209 Orange St., Wilmington, New Castle, DE, 19801, USA ("Pharmosa Therapeutics"), owns, by assignment, partial right, title, and interest in PCT Application No. PCT/US19/30841, entitled PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF TREPROSTINIL, and any invention claimed therein; and

Pharmosa Biopharm Inc., a Taiwan corporation having offices at 3F-3, No.66, Sanchong Rd., Nangang Dist., Taipei City 11560, Taiwan ("Pharmosa Biopharm"), desires to own Pharmosa Therapeutics' entire right, title, and interest in and to the invention, in the United States (35 U.S.C. §100), and in and to PCT Application No. PCT/US19/30841.

NOW THEREFORE, be it known that, for good and valuable consideration, receipt of which is hereby acknowledged, Pharmosa Therapeutics hereby sells, assigns, transfers, and sets over to Pharmosa Biopharm, its lawful successors and assigns, Pharmosa Therapeutics' entire right, title, and interest in and to PCT Application No. PCT/US19/30841, the invention claimed therein, any other United States patent application directed to the invention, and all Letters Patent of the United States that may be granted thereon, and foreign countries which may be obtained therefor, and all reissues, reexaminations, and extensions thereof; and all rights to claim priority on the basis of such application; and Pharmosa Therapeutics hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States to issue all Letters Patent for this invention to Pharmosa Biopharm, its successors and assigns, in accordance with the terms of this Assignment;

AND, Pharmosa Therapeutics HEREBY further covenants that Pharmosa Therapeutics has the full right to convey the interest assigned by this Assignment, Pharmosa Therapeutics will take all action and execute all documents necessary to perfect the interest assigned hereby, and Pharmosa Therapeutics has not executed and will not execute any agreement in conflict with this Assignment;

AND, Pharmosa Therapeutics HEREBY further covenants and agrees that Pharmosa Therapeutics, through its officers and employees, will, without further consideration, communicate with Pharmosa Biopharm, its successors and assigns, any facts known to Pharmosa Therapeutics and its officers and employees respecting the invention and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver all papers that may be necessary or desirable to perfect the title to the invention in said Pharmosa Biopharm, its successors and assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths, and generally aid Pharmosa Biopharm, its successors and assigns, to obtain and enforce proper patent protection for the invention in the United States.

Docket No. 203-011PCT

IN TESTIMONY WHEREOF, Pharmosa Therapeutics has caused its authorized representative to execute this Assignment.

Pharmosa Therapeutics, Inc.

By Wen-Hsu Yen

Date 05 Aug. 2020

Pharmosa Biopharm Inc.

By Wen-Hsu Yen

Date 05 Aug. 2020

PATENT

RECORDED: 01/18/2022

REEL: 058684 FRAME: 0202